The following information may help to address your question:
According to the practice guidelines set forth by the American College of Obstetrics and Gynecology, women with familial thrombophilic syndromes, including factor V Leiden mutation, have an increased risk of venous thromboembolism during oral contraceptive use and also developing venous thromboembolism earlier during use than lower risk users. An initial study concluded that women with a factor V Leiden mutation had an eight-fold increased risk of venous thromboembolism than did women without the mutation. The risk was more than 30 times higher in carriers who used oral contraceptives than in non-oral contraceptive users who were not carriers of the mutation. However, most of these women will never experience venous thromboembolism, even if they used combination oral contraceptives.You can find a list of brand names of oral contraceptives at the following link from MedlinePlus, the National Library of Medicine Web site designed to help you research your health questions.